Express blood test for cancer detection, early colorectal cancer screening test launched, with a sensitivity of 91%

▎WuXi AppTec Content Team Editors Today, Guardant Health announced the launch of the Shield blood test to detect early signs of colorectal cancer in adults at average risk
.

This is the company's first blood-based early-stage colorectal cancer screening test
.

Colorectal cancer can usually be cured with surgery if caught early
.

However, current screening methods, including colonoscopy, or stool-based tests, can be uncomfortable for participants, time-consuming, or difficult to complete
.

This results in people who should be screened not being screened
.

Guardant Health's press release states that 75% of patients who die from colorectal cancer fail to receive recommended screenings on time
.

The Shield test is a screening test for early signs of cancer based on the detection of cell-free DNA fragments released by tumors in the blood
.

It only requires a sample obtained from a routine blood draw
.

For cancer treatment, being able to detect cancer at an early stage maximizes the chance of curing the disease
.

At the 2022 WuXi AppTec Health Forum held recently, Dr.
Harold Burstein, a professor at Harvard Medical School and a doctor at Dana-Farber Cancer Institute, said that early screening tools developed based on cell-free DNA and other biomarkers in blood will have a future in the future.
A decade promises to revolutionize cancer treatment
.

The clinical performance of this test was validated on 309 patient samples, including 92 colorectal cancer samples, 166 normal samples and 51 advanced adenoma samples
.

Results of the clinical trial showed that the Shield assay demonstrated 91% sensitivity for colorectal cancer, 90% for Stage I disease, 97% for Stage II and 86% for Stage III disease
.

In normal samples, the test showed a specificity of 92 percent
.

"The launch of the Shield test represents an important milestone in our commitment to revolutionizing cancer screening
.

We are committed to developing highly sensitive technology that can detect early-stage cancers with a simple blood draw,
"
said Mr.
AmirAli Talasaz, Co-CEO, Guardant Health.
"Screening for colorectal cancer is just the beginning, and we will rapidly expand screening across multiple cancer types, including lung, pancreatic and other cancer types
.

We believe early cancer screening saves lives
.

" Reference: [1] Guardant Health Announces Shield ™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults.
Retrieved May 2, 2022, from https://investors.
guardanthealth.
com/press-releases/press-releases/2022/Guardant-Health- Announces-Shield-Blood-Test-Available-in-US-to-Detect-Early-Signs-of-Colorectal-Cancer-in-Average-Risk-Adults/default.
aspxDisclaimer: WuXi AppTec content team focuses on introducing global Advances in Biomedical Health Research
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.